Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
-
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
-
Korean Ministry of Food and Drug Safety Approves Omitting Cohort 4 and Dosing Cohort 5 with Six Daily Subcutaneous Doses of Next-Generation Coagulation Factor IX Current lower doses are predicted...
-
Former Novo Nordisk Executive Strengthens Catalyst’s Hemophilia Expertise SOUTH SAN FRANCISCO, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage...
-
Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN...
-
Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN...
-
-- Appoints Arwa Shurrab as Vice President of Regulatory Affairs and Jamie Ellen Siegel, M.D., as Head of Clinical Development -- SOUTH SAN FRANCISCO, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) --...
-
-- Phase 1/2 trial of Factor IX CB 2679d is advancing with interim results expected by year-end -- -- Phase 2 trial of Factor FVIIa marzeptacog alfa (activated) on track for initiation by year-end-- ...
-
CB 2679d demonstrated a 22-fold greater potency over BeneFIX and a longer mean residence time SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc....
-
Senior pharmaceutical executive with extensive experience in hematology and hemophilia Led Baxalta’s Global Blood Disorders Franchise within the Hematology Division SOUTH SAN FRANCISCO, Calif., Oct....